Excelmab Snares ￥10M in Series A+ Round, Developing Bispecific Antibodies for Cancer

According to 36Kr.com, Excelmab Inc. ("Excelmab") has closed its series A+ funding round, with participation from Korea Investment Partners, CAS Investment Management, Medfine Capital, Elite Capital, and others. Proceeds of this round will mainly be used for the research and development of bispecific antibodies, as well as the application of clinical trials of bispecific antibodies for breast cancer.

Excelmab was established by Dr. Wenjun Zhang in 2016 in Guangzhou China. With its novel bispecific antibody platform, Excelmab has developed a series of anti-tumor bispecific antibody drugs, devoted to providing efficient and cost-effective drugs for cancer patients at home and abroad, and at the same time improving China's innovation ability and technical level in the biopharmaceutical field.  

At present, Excelmab has made promising research achievements in the field of various cancer treatments, such as gastric cancer, breast cancer, lung cancer, and other directions.

Excelmab has developed two leading products. One is the CD3-centered bispecific antibody, and three such kinds of drugs have passed the chemotaxis research. The other is immune checkpoint inhibitors based on various pathways of immune checkpoints, which can make the immune system reactivated. Currently, Excelmab has found several candidate antibodies for multiple immune checkpoints through the antibody discovery and validation platform, and those candidates have passed the biological verification and chemotaxis research.

KIP is a leading venture capital & private equity firm that has over 30 years of experience in providing venture capital to bold and innovative entrepreneurs who want to change the world. KIP manages over 20 venture and private equity funds with US$1.8 billion in total assets under management.

CASI' s controlling shareholder is Chinese Academy of Sciences Holdings Co., Ltd. As a Chinese PE fund manager, CASI has supported over 300 scientific and technological payoffs for industrialization in succession, some of which has become industrial bellwethers, and has contributed to the promotion of scientific achievement conversion and technological progress.